Literature DB >> 25119569

[Germ cell and embryonal tumors].

W Reith1, R Mühl-Benninghaus, A Simgen, U Yilmaz.   

Abstract

Germ cell tumors, which constitute approximately 3-5% of tumors of the central nervous system (CNS), can be subdivided into germinomas, embryonal carcinomas, yolk sac tumors, choriocarcinomas, teratomas and mixed germ cell tumors. The diagnosis of intracranial germ cell tumor is based on the clinical symptoms, detection of tumor markers, such as alpha fetoprotein (AFP) and the beta subunit of human chorionic gonadotropin (beta-hCG) in blood and cerebrospinal fluid (CSF), magnetic resonance imaging (MRI) of the brain and spinal cord, CSF cytology and histology. The diagnosis of a secreting germ cell tumor, i.e. a non-germinoma, can be made by the determination of AFP and hCG as tumor markers. Germinomas are radiosensitive but are equally as sensitive to chemotherapy. Teratomas of the CNS are mostly diagnosed in newborns and infants. The most decisive role in the treatment of teratomas is played by as complete a resection as possible. Chemotherapy and irradiation play a subordinate role.Embryonal tumors, which constitute approximately 15-20% of CNS tumors, include medulloblastomas, primitive neuroectodermal tumors (PNET) of the CNS and the atypical teratoid rhabdoid tumor of the CNS. Medulloblastoma is the most common malignant brain tumor in childhood and adolescence. The incidence peak is the fifth year of life with a male predisposition in a ratio of 1.5:1. Medulloblastomas constitute 12-25% of all pediatric CNS tumors and 30-40% of pediatric tumors of the posterior cranial fossa. At the time of diagnosis evidence of dissemination in the CSF cavity is found in approximately 40% of patients. The extreme cell density makes medulloblastomas hyperdense in computed tomography (CT) and can therefore be differentiated from hypodense astrocytomas. The PNETs are histologically related to medulloblastomas, pineoblastomas, atypical teratoid rhabdoid tumors and peripheral neuroblastomas. They are relatively rare in children constituting less than 5% of supratentorial neoplasms. Patients are mostly clinically conspicuous due to macrocephalus and signs of brain pressure and/or seizures. In native CT the solid components of PNETs show a hyperdensity compared to the surrounding brain parenchyma probably due to the high cell density. Cysts and calcification are often detectable. The survival rate of children with CNS tumors has continuously increased in recent years. When corresponding clinical symptoms appear, such as headache, nausea or vomiting when fasting, all of which are evidence of increased intracranial pressure, MRI should be carried out as quickly as possible. Children should be treated in centers with departments of pediatric oncology and hematology and within the framework of studies.

Entities:  

Mesh:

Year:  2014        PMID: 25119569     DOI: 10.1007/s00117-014-2667-x

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  13 in total

1.  Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.

Authors:  André O von Bueren; Katja von Hoff; Torsten Pietsch; Nicolas U Gerber; Monika Warmuth-Metz; Frank Deinlein; Isabella Zwiener; Andreas Faldum; Gudrun Fleischhack; Martin Benesch; Juergen Krauss; Joachim Kuehl; Rolf D Kortmann; Stefan Rutkowski
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis.

Authors:  J Lee Villano; Irim Y Virk; Vanessa Ramirez; Jennifer M Propp; Herbert H Engelhard; Bridget J McCarthy
Journal:  Neuro Oncol       Date:  2009-12-21       Impact factor: 12.300

3.  Teratomas in infancy and childhood.

Authors:  U Göbel; G Calaminus; J Engert; P Kaatsch; H Gadner; J P Bökkerink; R J Hass; K Waag; M E Blohm; S Dippert; C Teske; D Harms
Journal:  Med Pediatr Oncol       Date:  1998-07

Review 4.  Tumors of the central nervous system in children and adolescents.

Authors:  Michael C Frühwald; Stefan Rutkowski
Journal:  Dtsch Arztebl Int       Date:  2011-06-03       Impact factor: 5.594

5.  Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89.

Authors:  M Bamberg; R D Kortmann; G Calaminus; G Becker; C Meisner; D Harms; U Göbel
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

6.  AFP/beta-HCG secreting CNS germ cell tumors: long-term outcome with respect to initial symptoms and primary tumor resection. Results of the cooperative trial MAKEI 89.

Authors:  G Calaminus; M Bamberg; D Harms; H Jürgens; R D Kortmann; N Sörensen; O D Wiestler; U Göbel
Journal:  Neuropediatrics       Date:  2005-04       Impact factor: 1.947

Review 7.  Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups.

Authors:  U Göbel; D T Schneider; G Calaminus; R J Haas; P Schmidt; D Harms
Journal:  Ann Oncol       Date:  2000-03       Impact factor: 32.976

8.  Treatment results of intracranial germinoma as a function of the irradiated volume.

Authors:  Y Shibamoto; M Abe; J Yamashita; M Takahashi; M Hiraoka; K Ono; K Tsutsui
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-08       Impact factor: 7.038

9.  Postoperative imaging after brain tumor resection.

Authors:  M Warmuth-Metz
Journal:  Acta Neurochir Suppl       Date:  2003

10.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088

View more
  1 in total

Review 1.  [Degenerative cerebellar diseases and differential diagnoses].

Authors:  W Reith; S Roumia; P Dietrich
Journal:  Radiologe       Date:  2016-11       Impact factor: 0.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.